SCHEMBL1558090

SCHEMBL1558090

CCONC(=O)c1ccccc1N

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.59
HSD17B10 Q99714 7/20 0.59
CFTR P13569 1/20 0.55
KDM4E B2RXH2 10/20 0.53
HPGD P15428 7/20 0.53
RCE1 Q9Y256 1/20 0.50
TP53 P04637 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.46
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
FADS1 O60427 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10585897 0.82 KDM4E (0.55) ALDH1A1HSD17B10KDM4EHPGDTP53
SCHEMBL2160841 0.81 ALDH1A1 (0.65) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL143432 0.81 ALDH1A1 (0.49) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL10785014 0.81 ALDH1A1 (0.49) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL692347 0.79 ALDH1A1 (0.66) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL28102741 0.79 ALDH1A1 (0.51) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL3636008 0.79 NPC1 (0.65) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL27755279 0.78 AKR1C3 (0.50) ALDH1A1RAB9ANPC1
SCHEMBL30823003 0.78 NPC1 (0.49) ALDH1A1HSD17B10CFTRKDM4EHPGD
SCHEMBL7963355 0.78 ALDH1A1 (0.62) ALDH1A1HSD17B10CFTRKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102124000-B Pyridine compounds ASTRAZENECA AB 2014-09-17 CN disclosed
EP-2303861-B1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2014-04-23 EP disclosed
US-8569298-B2 Pyridine compounds ASTRAZENECA AB (SE) 2013-10-29 US disclosed
CN-102124000-A Pyridine compounds ASTRAZENECA AB 2011-07-13 CN disclosed
US-20110166139-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2011-07-07 US disclosed
EP-2303861-A1 PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2011-04-06 EP disclosed
WO-2009153589-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166139-A1 PYRIDINE COMPOUNDS PTK2, PTK2B, PFKP ALDH1A1 2505/4885HSD17B10 4826/4885CFTR 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.